MediWound burn therapy NexoBrid launched in US (MDWD)


Israeli biopharma company MediWound (NASDAQ:MDWD) said its wound care product NexoBrid has been commercially launched in the US through partner Vericel.

NexoBrid, also known as anacaulase-bcdb, is an enzymatic therapeutic for the non-surgical removal of non-viable tissue from patients who have sustained

Source link

Related Articles

Back to top button